400 attendees, 25 speakers, 7 countries represented and a bright future ahead for clinical research!
Celebrating Bioforum’s 20th anniversary in the heart of Tel Aviv, the 2018 Bioforum Summit Partnering for Clinical Research covered the hottest topics in the future of clinical trials with leading KOLs from around the world.
Bioforum was established with the mission to bridge the gap between industry, academia and government in the life sciences space. The company has a Data Focused CRO office in Israel and Victoria’s capital city of Melbourne and has partnered with the State Government to strengthen the ties between the vibrant Israeli and Victorian ecosystems. Featuring key speakers from the biotech sector including Victoria’s Lead Scientist Dr Amanda Caples, the Victorian Government sent a significant delegation to the Summit in order to learn the Israeli landscape. For a week, delegates met with Israeli startups, researchers and regulators, academic and industry service providers in order to identify opportunities for collaboration in clinical trials.
Israeli companies carrying out clinical trials in Victoria can take advantage of up to 41 per cent cashback on R&D expenditure. A cost comparison found conducting clinical trials in Australia was 28 per cent cheaper than the United States, 60 per cent cheaper after-tax incentives.
Like Israel, Victoria has benefited from supportive government investing in biotech infrastructure to attract investment. In the past 15 years, successive Victorian Governments have invested more than $1.8 billion in building science and technology industries.
The Victorian Government is also investing in the relationship with Israel, setting up its own office in the heart of Tel Aviv, supported by the Australia-Israel chamber of Commerce. It has appointed a Director of Victorian Government Biomedical Trade and Investment for the sole purpose of strengthening the business ties between the countries specifically in the life sciences space.
The successful collaborations already underway have been highlighted with the signing of an MOU between the Israeli Industry Network for Advanced Cell Applications and the Center for Commercialization of Regenerative Medicine (CCRM) Australia. The MOU was signed in a closed event for leaders of the Israeli biotech community In the presence of the Victorian lifesciences delegation to Israel, led by Dr Caples, and by the CEO of CCRM Australia, Mr. Silvio Tiziani.